Work

Activity of novel antifungal compound APX001A against a large collection of Candida auris

Year: 2018

Type: article

Abstract: Background: APX001A is an antifungal agent that targets a novel pathway-glycosylphosphatidylinositol glycolipid biosynthesis. It has been shown to be effective against a variety of fungal species, including Candida spp., Aspergillus spp. and other filamentous fungi. Objectives: To determine the activity of APX001A against the emerging fungal pathogen Candida auris. Methods: APX001A was tested by broth microdilution against 100 geographically distinct isolates of C. auris. Results: APX001A showed activity against all isolates, including some that were resistant to one or more antifungals, with MIC50 and MIC90 of 0.002 and 0.008 mg/L, respectively. Conclusions: These findings suggest that APX001A shows encouraging activity against the emerging fungal pathogen C. auris.

Source: Journal of Antimicrobial Chemotherapy

DOI: 10.1093/jac/dky302

Authors: Elizabeth L Berkow, Shawn R Lockhart

Institution: Centers for Disease Control and Prevention

Language: English

Topic: Antifungal resistance and susceptibility

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,784